Chardan Lifts Price Target on Intellia Therapeutics to $30 From $27, Keeps Buy Rating<blockquote>Chardan 将 Intellia Therapeutics 的目标价从 27 美元上调至 30 美元,维持买入评级</blockquote>
Intellia Therapeutics (NTLA) has an average rating of overweight and mean price target of $26.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f